Furthermore, we analysed how different forms of TRAIL affect the production of potentially side-effect-causing cytokines [47,48,49], and how this problem could be overcome by testing different sensitisation approaches in TRAIL resistant prostate cancer cells. This evidence concerns the gene TNFSF10 and prostate carcinoma.